Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Key facts

Sponsor

Fred Hutchinson Cancer Center

Principal Investigator

Mohamed Sorror

Fred Hutch/University of Washington Cancer Consortium

Intervention

Allogeneic Bone Marrow Transplantation(procedure)

Enrollment

16 enrolled

Eligibility

75 years · All sexes

Timeline

2010 – 2018

Study locations (2)

• Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
• Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell prolymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT05418088
  Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
  Sumithira Vasu
• ACTIVE NOT RECRUITINGPHASE1NCT02153580
  Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
  City of Hope Medical Center
• ACTIVE NOT RECRUITINGPHASE2NCT02007044
  Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT01589302
  PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
  Kami Maddocks, MD

See all trials for B-cell prolymphocytic leukemia →